CARMA

Child and Adolescent Reservoir Measurements on early suppressive ART (CARMA)

CARMA was a multi-centre, cross sectional study of children and adolescents with perinatally acquired HIV-1 on sustained suppressive antiretroviral therapy commenced before 2 years of age. 40 children and adolescents treated with ART in the first 24 months of life and virally suppressed for at least 5 years participated in this study. They were recruited from 6 major European HIV clinical research centres based in Italy, Spain and United Kingdom.

The CARMA study began in November 2017 and ended in March 2018

Study Aim

The CARMA study aimed to identify the factors that influence the establishment of a low total HIV DNA in children and adolescents perinatally infected with HIV-1 on suppressive antiretroviral therapy.

Why is CARMA important?

Immunotherapeuutic strategies to achieve ART free viral remission in people with chronic HIV infection in whom reservoirs are established, are likely to be most effective in those with marked restriction in HIV proviral reservoir size following early antiretroviral therapy. Identifying virological and immunological characteristics after suppressive ART for perinatal infection and identifying factors and biomarkers associated with limited HIV proviral reservoir size are critical to identify study participants for future proof-of-concept studies aimed at inducing ART free HIV viral remission.


The CARMA study was sponsored by Penta